---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-23-000025"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T08:50:47.754006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q4 revenue flat YoY; non-GAAP EPS $3.31, guides FY2023 ~6-7% growth

## Summary
- Q4 net sales $730.3M, -0.3% reported; currency-neutral +5.8% (+10.6% ex-COVID).
- Life Science segment $359.7M (+10.1%); Clinical Diagnostics $369.6M (-8.7%).
- GAAP net income $827.7M ($27.78 diluted) from Sartorius fair value; non-GAAP net income $98.5M ($3.31).
- Full-year 2022 net sales $2,802.2M (-4.1%); non-GAAP EPS $14.42 vs $15.94 prior year.
- FY2023 outlook: non-GAAP currency-neutral revenue growth ~6-7%, non-GAAP operating margin ~19.5%.

## SEC filing metadata
- accession: 0000012208-23-000025
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/bio-20230216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-23-000025
- JSON: https://secwatch.observer/filing/0000012208-23-000025.json
- Plain text: https://secwatch.observer/filing/0000012208-23-000025.txt

## Key facts
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported Fourth-quarter 2022 results: revenue $730.3 million, net income $827.7 million, EPS $27.78 per share, on a diluted basis.
  - Period: Fourth-quarter 2022
  - Revenue: $730.3 million
  - Net income: $827.7 million
  - EPS: $27.78 per share, on a diluted basis
  - Result: reported results
  source text: Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 percent compared to $732.8 million reported for the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported the full year ended December 31, 2022 results: revenue $2,802.2 million.
  - Period: the full year ended December 31, 2022
  - Revenue: $2,802.2 million
  - Result: reported results
  source text: On a reported basis, net sales for the full year 2022 decreased 4.1 percent to $2,802.2 million compared to $2,922.5 million for the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.